BioTech Medics (BMCS) Ratios
BioTech Medics Ratios
BMCS's free cash flow for Q4 2024 was $52.11K. For the 2024 fiscal year, BMCS's free cash flow was decreased by $-4.00 and operating cash flow was $52.11K. See a summary of the company’s cash flow.
| Ratios | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 |
| Quick Ratio | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 |
| Cash Ratio | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 |
| Solvency Ratio | 0.38 | 0.27 | -0.26 | 0.52 | 1.03 |
| Operating Cash Flow Ratio | -0.06 | -0.04 | -0.56 | -0.16 | 0.00 |
| Short-Term Operating Cash Flow Coverage | -1.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -431.68K | $ -426.06K | $ -328.41K | $ -187.15K | $ -107.11K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.00 | 1.01 | 1.00 | -0.00 | 0.00 |
| Debt Service Coverage Ratio | 13.10 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.14 | 0.00 | -0.01 | -0.00 | 0.00 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 119.99% | 100.00% | 100.00% | 71.11% | 100.00% |
| Return on Assets (ROA) | -0.01% | -0.16% | -0.46% | -28709.42% | 0.00% |
| Return on Equity (ROE) | -0.01% | -0.17% | -0.46% | 58.72% | 57.33% |
| Return on Capital Employed (ROCE) | -0.00% | -0.17% | -0.46% | 82.57% | 57.33% |
| Return on Invested Capital (ROIC) | 0.14% | -0.17% | -0.46% | 82.57% | 57.33% |
| Return on Tangible Assets | -0.01% | -0.16% | -0.46% | -28709.42% | 0.00% |
| Earnings Yield | -0.08% | -6.94% | -2.34% | -3.19% | -7.06% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 |
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -91.02 | -79.40 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -91.02 | -79.40 | 0.00 |
| Operating Cash Flow Coverage Ratio | -1.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -0.37% | -1.01% | -1.34% | -0.87% | 0.00% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1291.71 | -14.41 | -42.66 | -31.37 | -14.17 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.07 | 0.02 | 0.20 | -18.42 | -8.12 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -270.06 | -98.92 | -74.77 | -114.70 | 0.00 |
| Price-to-Operating Cash Flow Ratio | -270.08 | -98.92 | -75.59 | -116.15 | 0.00 |
| Price-to-Earnings Growth (PEG) Ratio | 12.92 | 0.23 | -0.19 | -0.47 | 0.00 |
| Enterprise Value Multiple | 39.22 | -14.41 | -160.01 | 35.60 | 7.88 |
| Enterprise Value | 7.29M | 1.66M | 13.76M | 3.44M | 870.13K |
| EV to EBITDA | 39.22 | -14.41 | -160.01 | 35.60 | 7.88 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -271.06 | -98.92 | -74.77 | -114.70 | 0.00 |
| EV to Operating Cash Flow | -271.08 | -98.92 | -75.60 | -116.15 | 0.00 |
| Tangible Book Value Per Share | 0.49 | 0.34 | 0.34 | -0.00 | -0.00 |
| Shareholders’ Equity Per Share | 0.49 | 0.34 | 0.34 | -0.00 | -0.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 29.85 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | -0.31 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 4.78 | 0.15 | 0.56 | 0.27 | 0.00 |
Currency in USD
